Madrigal recently released their 3rd quarter financial report.  They said they were very pleased and the invester community loved it pushing the Madrigal stock price up dramatically.  Take a look at this summary.

You can see that nearly 7,000 patients are now taking the drug and that most insurers are covering the treatment.  I'm happy for those who have the opportunity but notice the prescriber number.  That 40% disturbs me.

OK, I may just be an overly emotional patient, but let's look at this in a bit of detail. Madrigal has identified that 315,000 patients have been diagnosed with F2/F3 MASH/NASH.  They have also identified the physicians who are most important in the management of those patients and have been trying to educate them for some time about the drug.  These are people who have been telling patients for years that they have liver disease and are sorry but there is no treatment.  We have all heard that sympathetic story.  Now we have treatment, so why have 60% of the top liver docs not yet written even one prescription?

Those physicians are seeing patients every day.  Are they simply unaware of the drug?  It would be a real indictment of their professional status if that were true, so I assume they know.  So why the decision not to engage?  In these several months, it is inconceivable that none of their patients qualified for the therapy.  

I care because of this data.

This shows how dangerous various conditions are compared to someone without the disease.  Basically, how likely are you to die compared to if you didn't have it.

Note that with F4 you are almost 11 times as likely to die, which is why we are so anxious for therapy for advanced disease. Rezdiffra is approved for F2/F3.  You can see that F2 is more dangerous than smoking and lots of attention is paid to that problem while the liver patient is expected to be quiet and wait until it gets worse. Just think about all the attention paid to diabetes, which is less than half the risk of F3. That really bugs me.

If you are an F2/F3 and have been ignored or your appointment is coming up, you need to speak up and ask the questions about whether Rezdiffra is appropriate for you.  It may not be, but if you could benefit you shouldn't just be passed along until next year.

Day to day living can be challenging when dealing with a disease.  Many people don't know what services are available to them in their local area. Finding those local resources in their local zip code is often a challenge for patients. We are developing a tool to help with that. Would you take a few minutes and examine our tool for locating local services?  Just click on the link below: enter your local zip-code in the form: explore how the services available to you in your area are shown: and take the short survey. The elements above the zip code function are under development, so don't comment on those just yet.

The Wellness League Local Search Tool

I will really appreciate it if you take this few minutes to give us feedback. As patients ourselves, how to live in the best way possible while dealing with illness is important. Your opinion matters.